Literature DB >> 17890029

Clusterin antisense complexed with chitosan for controlled intratumoral delivery.

Christopher M Springate1, John K Jackson, Martin E Gleave, Helen M Burt.   

Abstract

The purpose of this work was to characterize an injectable, intratumoral, controlled release delivery system for clusterin antisense oligonucleotide (clusterin ASO) based on clusterin ASO complexed with chitosan microparticles (CC complexes) and blended with a biodegradable polymeric paste (CC in paste). The effect of clusterin ASO/chitosan ratio on the physicochemical properties of CC complexes and the influence of chitosan and polymeric paste on the in vitro release and stability of clusterin ASO were investigated. Chitosan had an intrinsic pK(a) of 6.2. Chitosan particles incubated at different pHs swelled to approximately 600% of their dry weight and had a mean diameter of approximately 200microm. As the amount of chitosan in CC complexes was increased or as the pH was decreased, zeta potentials became increasingly less negatively charged and the amount of clusterin ASO complexed with chitosan increased. Clusterin ASO released into PBS or plasma in vitro from polymeric paste and CC in paste in a similar manner with a burst phase of release followed by a slow sustained release. The ratio of clusterin ASO to chitosan and incorporation into polymeric paste influenced the rate and extent of clusterin ASO release. Inclusion of clusterin ASO with or without chitosan in polymeric paste inhibited the in vitro degradation of clusterin ASO in plasma. Treatment of PC-3 cells in vitro with clusterin ASO alone or clusterin ASO released from the various formulations resulted in 52-62% inhibition of the expression of clusterin protein. Degradation studies showed that approximately 40% of the full-length clusterin ASO remained from both clusterin ASO alone and CC complex samples when incubated in 50% plasma in vitro for 4 days. In conclusion, the amount of clusterin ASO loaded into microparticulate chitosan was dependent on the amount of chitosan present and the pH of the environment and clusterin ASO released from the various formulations in a controlled manner and in a bioactive form.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890029     DOI: 10.1016/j.ijpharm.2007.08.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.

Authors:  Veronika Schmitt; Claudia Kesch; John K Jackson; Samir Bidnur; Eliana Beraldi; Virginia Yago; Mary Bowden; Martin E Gleave
Journal:  Pharm Res       Date:  2020-01-21       Impact factor: 4.200

2.  The application of layered double hydroxide clay (LDH)-poly(lactide-co-glycolic acid) (PLGA) film composites for the controlled release of antibiotics.

Authors:  Michelle Chakraborti; John K Jackson; David Plackett; Samuel E Gilchrist; Helen M Burt
Journal:  J Mater Sci Mater Med       Date:  2012-04-20       Impact factor: 3.896

3.  Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery.

Authors:  Yanhui Jia; Mei Yuan; Huidong Yuan; Xinglu Huang; Xiang Sui; Xuemei Cui; Fangqiong Tang; Jiang Peng; Jiying Chen; Shibi Lu; Wenjing Xu; Li Zhang; Quanyi Guo
Journal:  Int J Nanomedicine       Date:  2012-03-28

4.  The use of nanocrystalline cellulose for the binding and controlled release of drugs.

Authors:  John K Jackson; Kevin Letchford; Benjamin Z Wasserman; Lucy Ye; Wadood Y Hamad; Helen M Burt
Journal:  Int J Nanomedicine       Date:  2011-02-10

Review 5.  Nonviral delivery systems for antisense oligonucleotide therapeutics.

Authors:  Si Huang; Xin-Yan Hao; Yong-Jiang Li; Jun-Yong Wu; Da-Xiong Xiang; Shilin Luo
Journal:  Biomater Res       Date:  2022-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.